WO1984001389A1 - Caracterisation et analyses d'oncogenes - Google Patents

Caracterisation et analyses d'oncogenes Download PDF

Info

Publication number
WO1984001389A1
WO1984001389A1 PCT/US1983/001517 US8301517W WO8401389A1 WO 1984001389 A1 WO1984001389 A1 WO 1984001389A1 US 8301517 W US8301517 W US 8301517W WO 8401389 A1 WO8401389 A1 WO 8401389A1
Authority
WO
WIPO (PCT)
Prior art keywords
oncogene
proto
dna
protein
gene
Prior art date
Application number
PCT/US1983/001517
Other languages
English (en)
Inventor
Robert A Weinberg
Clifford James Tabin
Scott M Bradley
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Priority to DE8383903635T priority Critical patent/DE3382098D1/de
Priority to JP58503483A priority patent/JPH0642840B2/ja
Priority to AT83903635T priority patent/ATE59412T1/de
Publication of WO1984001389A1 publication Critical patent/WO1984001389A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Definitions

  • This invention is in the field of molecular biology and more specifically relates to defining differences between mutant alleles and their corresponding wild type alleles, particularly oncogenes, and proto-oncogenes, and to assays which take advantage of such differences.
  • resear ⁇ chers have attempted to identify and study DNA segments in tumor cells, often referred to as ""oncogenes," whose alteration is critically important for oncogenic conversion.
  • Oncogenes whose alteration is critically important for oncogenic conversion.
  • One recent approach to isolation of an oncogene involved the transfer of tumor cell DNA from the EJ bladder carcinoma cell line into non-transformed NIH3T3 mouse fibroblasts. It was discovered that the phenotype of cellular trans ⁇ formation could be passed from cell to cell in this manner. Tumor DNA was able to induce foci of transformed cells in the recipient N H monolayer culture while DNA from normal, untransformed donor cells failed to produce foci. See Shih, C. , Shilo, B_, Goldfarb, M.P., Dannenberg, A.
  • the marker used in this work was an Alu DNA sequence, which is repeated about 300,000 times in human DNA, but is not present in mouse fibroblast DNA.
  • the interspecies transfection thus resulted in the ultimate selection of a cell containing the oncogene of interest and its associated marker. All DNA from this transfected cell was employed in the- creation of a genomic library in a lambdaphage and the appropriate chimeric lambdaphage was then selected using a probe specific for the human Alu marker.
  • v-Ha-ras This rat sarcoma virus gene, termed v-Ha-ras, had been acquired from the rat genome during the process of formation of the chimeric viral genome. See Scolnick, E.M. and Parks, W.P. J. Virol. 13; 1211-1219 (1974); and, Shih, T.Y., Williams, D.R., Weeks, M.O., Maryak, J.M. , Vass, W.C. and Scolnick, E.M. J. Virol. 27; 45-55 (1978) .
  • This invention relates to an investigation of the differences between the EJ oncogene, previ ⁇ ously shown to cause human bladder cancer, and its proto-oncogene.
  • the procedures involved can be applied to defining differences between any mutant allele and its corresponding wild type allele; the procedures are particularly useful in defining the differences between oncogenes and proto-oncogenes.
  • experiments were performed to determine whether the dramatic functional differ ⁇ ence between the EJ oncogene and its proto-onco ⁇ gene were due to a regulation mechanism or to one of sequence differences. These experiments provide a data indicating that upregulation of this gene was not responsible for cellular trans ⁇ formation. Thus, it was concluded that the dramatic functional differences must be due to changes in the DNA sequence of said genes.
  • the area of the 6. 6 kb pEJ responsible for cellular transformation in NIH3T3 fibroblasts was narrowed to a 350 kb segment by a series of in vitro recombinations. This 350 kb segment was then sequenced for the oncogene and proto-onco ⁇ gene, and it was found that single base substitu ⁇ tions accounted for the difference at the 60th nucleotide from the Xmal restriction site. This substitution in the codon for gly ⁇ ine (Gly 12) , normally occurring as- GGC, was changed to the sequence GTC, which codon expresses valine.
  • Figure 1A presents electrophoreti ⁇ gel patterns of total cellular RNA obtained from both normal and transformed bladder cells, which patterns were visualized by autoradiography;
  • Figure IB presents electrophoretic gel patterns obtained by precipitation of etaboli- cally labelled protein lysates from both EJ and normal bladder cells employing monoclonal antisera against the v-Ha-ras p21 protein;
  • Figure 2A presents electrophoretic gel patterns of cellular DNA from four cell lines transfected with pEJ or pEC;
  • Figure 2B presents electrophoretic gel patterns of total polyadenylated RNA from the same four transfected cell lines
  • Figure 2C presents electrophoretic gel patterns of p21 protein immunoprecipitated from cell lysates of the same four transfected cell lines;
  • Figures 3A-3D are photographs taken through a phase-contrast microscope at 50OX magnification of four cell lines transfected with pEJ or pEC;
  • Figure 4 presents electrophoretic gel pat ⁇ terns of immunoprecipitated p21 protein from cells transfected with pEJ or pEC;
  • Figure 5 is a schematic illustration of in vitro genetic recombinants constructed from the EJ transforming gene and its normal cellular homo- logue and also contains a summary of transfection and transformation data for experiments conducted with such genetic recombinants;
  • Figure 6 presents electrophoretic gel pat ⁇ terns for migration of p21 proteins immuno ⁇ precipitated from cells transfected with in vitro recombinants of the EJ oncogene clone (pEJ) and its homologous proto-oncogene clone (pEC) ;
  • Figure 7 illustrates a comparison of the DNA sequence of the molecular clone of the EJ trans ⁇ forming gene and its non-transforming cellular homologue and also sets forth the amino acid sequence expressed for each;
  • Figure 8 presents electrophoretic gel pat ⁇ terns illustrating differences in fragments of clones of the EJ and EC genes created by the Nael restriction enzyme.
  • Figures 9 and 10 are block diagrams illus ⁇ trating assay protocols employing endonucleases or antisera against protein coded for by normal genes or transforming genes.
  • oncogene is used to mean a genetic sequence whose expression within a cell induces that cell to become converted from normal cell into a tumor cell.
  • proto-oncogene is used " herein to mean a genetic sequence, residing in the normal genome of a normal, non-tumor cell, which has the potential, when altered in the appropriate manner, of becoming an oncogene.
  • OMPI c-Ha-ras proto-oncogene
  • Hbl-5 a primary tissue culture explant from a five-month old human bladder grown on inactivated NIH3T3 feeder layers. This culture was grown out from fresh human bladder tissue and was shown to exhibit several of the properties expected of transitional bladder epithelium. It was free of underlying stromal material, and consequently represented a close counterpart of the cells front which the bladder carcinoma originated.
  • RNA was prepared by the technique of Varmus et al. See Var us, H. ⁇ ., Quintrell, N. and Ortiz, S. Cell 25; 23-36 (1981). Four microgra s of RNA was then fraction ⁇ ated by electrophoresis through formaldehyde-con- taining 2 percent agarose gels and transferred to nitrocellulose. A ras-specific probe was prepared by cutting pEJ with BamH , fractionating the resulting fragments through a 1 percent agarose gel and extracting the 6.6 kb insert with Nal and glass beads. The nick-translated fragment (6.6 x)
  • Figure 1A shows the relative levels of c-Ha-ras specific RNA in the two cell types; Lane 1, RNA from EJ cells; Lane 2, RNA from Hbl-5 cells. As can be seen, similar levels of RNA were detected in the two cultures and the transcripts had a size of 1.2 kb.
  • Ha-MuSV but not the p21 encoded by Ki-MuSV (Lanes lb and 2b) or a monoclonal antisera (Y13-259) which detects both the Ha-MuSV and Ki-MuSV ⁇ 21's
  • Figure IB shows a comparison of p21 proteins immunoprecipitated from cell lysates of EJ cell clones (Lanes 1, a- ⁇ ) and Hbl-5 cells (Lanes 2, a-c) .
  • OMPI oncogene probe reacted exclusively with tran ⁇ scripts of the human c-Ha-ras gene. Interpreta ⁇ tion of the protein data was less clear, but it was apparent that both cells had comparable levels of proteins that were reactive with the Harvey- specific serum, and that these proteins could collectively be termed n p21.”
  • bladder epi ⁇ thelial cells were not representative of normal precursors of bladder carcinoma cells.
  • Such a possibility might cloud interpretation since a ras gene could be expressed at a high level in one cell type without inducing transformation, and only achieve this phenotype when inappropriately expressed in a second cell type. Therefore, the levels of transcription and translation of the two genes in the same cellular background were mea ⁇ sured.
  • the ras- specific sequences were prepared from pEJ and used as a probe. Seventy-five percent of the non-transformed colonies transfected with the proto-oncogene and all of the transformed oncogene-transfected colonies showed the presence of pEJ-homologous sequences migrating at 6.6 kb. The positive colonies also had BamHI frag- ents of other sizes annealing to the probe.
  • RNA preparations were then run on a formaldehyde gel, transferred to nitrocellulose filters, and probed with ras- specific DNA.
  • the procedures previously described were employed and the results are shown in Figure 2B wherein the lanes are; Lane 1, RNA from NIH3T3 cells; Lane 2, EJ/Gpt-2 cells; Lane 3, EJ/Gpt-3 cells; Lane 4, EC/Gpt-1 cells; Lane 5, EC/Gpt-5 cells.
  • Cell lysates were prepared, immuno ⁇ precipitated and analyzed as previously described. The results are illustrated in Figure 2C as; immunoprecipitations with non-immune serum (Lanes 1, 2, 7, 8) or the monoclonal antiserum (Y13-238) which precipitates the Ha-MuSV p21 (Lanes 3-6) .
  • Cell lysates were prepared from EJ/Gpt-2 (Lanes 1, 3); EC/Gpt-1 (Lanes 2, 4); EJ/Gpt-3 (Lanes 5, 7) and EC/Gpt-5 (Lanes 6, 8).
  • OMPI while a comparable level of the proto-oncogene- specified p21 had no effect on cellular phenotype. Since the p21 proteins are the only apparent gene products encoded by these genes, it was concluded that the difference in function between the EJ oncogene and the proto-oncogene must derive from structural alterations in the p21 protein. Conversely, regulatory alterations did not appear critical to the transforming activity of the oncogene.
  • Schematic diagrams (Lane 5; ⁇ J/Gpt-3; Lane 6: EC/Gpt-1) show both the relative positions of the detected p21 bands and the relationships of those bands (arrows) based upon kinetic data and previously published experiments. See Shih, T.Y. efc al. J. Virol. 42; 253-261 (1982) .
  • Figure 4 may provide an explanation for the complexity of p21 proteins seen in normal and transformed bladder cells ( Figure lb) ; the normal cells exhibited two bands, reflective of the expression of a proto-oncogene; the carcinoma cells appeared to exhibit four bands, two being specified by the oncogene of these cells, and two by the normal, proto-oncogene of the other homologous chromosome.
  • the physical differences observed between p21 protein from oncogenes and proto-oncogenes might have reflected functionally important changes in
  • OMPI the p21 protein, or alternatively, might represent differences which did not affect the process of transformation.
  • a series of independent experiments was designed to localize genetically the regions of the oncogene that specified the altered migration rates of the protein and the change in the gene function. These experiments depended upon in vitro homolo ⁇ gous recombination between clones of the two genes.
  • the experimental strategy was to excise a restriction fragment out of the oncogene clone (pEJ) and use it to replace the homologous piece of the proto-oncogene clone (pEC) .
  • the reciprocal construction would be carried out by splicing the fragment of the proto-oncogene clone into the oncogene clone.
  • FIG. 5 presents a diagram of the specific constructions undertaken and a summary of the transfection and transformation data obtained.
  • the restriction map shows the cleavage sites for various enzymes within the 6.6 kb BamHI insert in pBR322. All sites specific for the enzymes are shown except for Xmal which acts in several other places which have not been well characterized.
  • the site shown is the only Xmal site between the first BstEII site and the Kpnl site.
  • the solid boxes on the map show the locations of coding exons.
  • pEJ/pEC chimeras are shown with segments derived from pEJ shown as solid bars and segments from pEC shown as open bars.
  • pEJ and pEC were cleaved with the indicated enzymes either to completion or in a partial digest as required to obtain each indicated fragment. The products were separated by electrophoresis through 1.2 percent agarose and eluted by melting a Nal and absorbing to glass beads. The fragment containing pBR322 was then treated with calf intestinal phosphatase.
  • the indicated fragments were joined either with the enzyme T4-DNA ligase or in a mock ligation without enzyme.
  • Constructs a-e were made in bimolecular ligations.
  • Constructs in f were made by mixing the three fragments simultaneously and in g and h by mixing the four fragments simultan ⁇ eously.
  • the ligation mixtures were directly transformed into the HB101 strain of E_ ⁇ coli. Only when colonies from mock ligations were less than 2 percent of the ligations were colonies analyzed for the presence of clones having appro ⁇ priate restriction maps. Twenty ng of each clone was transfected into NIH3T3 cells as previously described and then carried without selection until foci were visualized in 10-14 days.
  • results of the transfections are shown in the first column.
  • the second column shows the number of independent bacterial colonies screened and then transfected into NIH3T3 cells. It was vital to verify that the transforming clones were indeed chimeras of the mixed pEJ and pEC origin, rather than contaminants of one origin or the other. This was done in three ways. In the simpler constructions, involving ligations of two fragments at a time, the results obtained with amplified recombinant clones were verified by directly transfecting the unamplified products of ligation reactions and of mock ligations con ⁇ taining isolated fragments not treated with the ligase.
  • a second confirmation depended on the fact that the plasmids pEJ and pEC contained their respective cellular genes inserted in the pBR322 plasmid vector in opposite orientations.
  • the origin of one parent of a recombinant could be determined by diagnostic restriction digests of the flanking plasmid regions. Since contaminating pEC could itself not give a false positive result, any active clone carrying proto-oncogene flanking sequences must have arisen as a consequence of the acquisition of portions of the transforming gene.
  • NIH3T3 cells transformed with the EJ bladder tumor oncogene, its normal proto-oncogene, or recombinants between the two genes were first biologically cloned in 0.35 percent agar and then metabolically labelled with S-methionine for 18 hours. Lysates were prepared and immunoprecipi- tated (5 x 10 cpm of TCA-precipitable counts) by a monoclonal antibody which detected the p21 encoded by Ha-MuSV but not the p21 encoded by Ki-MuSV (Y13-172) . See Furth, M.E., David, L.J., Fleurdelys, B. and Scolnick, E.M. J. Virol.
  • Cell lysates were from: NIH3T3 cells (Lane 1) ; cells transformed with the proto-onco ⁇ gene [the LTR-activated 3kb SacI fragment described in Payne, G.S., Courtneidge, S.A. , Crittendon, L.B., Fadly, A.M., Bishop, J.M. and Varmus, H.E.
  • the short (350 kb) fragment shown to have biological significance was sequenced for DNA from the oncogene and the proto-oncogene. Sequences were determined by the forward and backward dideoxy DNA sequencing technique of Seif et al. and by the chemical procedure of Maxam and Gil ⁇ bert. See Seif, I. , Khoury, G. and Dhar, R. Nucl. Acid Res. 8; 2225-2238 (1980); and, Maxam, A.H. and Gilbert, W. Proc. Natl. Acad. Sci. USA 74; 560-564 (1977) . The results are illustrated in Figure 7 wherein the coding DNA strand is shown together with the inferred amino acid sequence.
  • GCCGGC occurs in the proto-oncogene, and thus represents a recognition site for the endonuclease NaeX.
  • This sequence also contains the CCGG recognition site of the endonuclease Hpal. Both of these are changed in the oncogene, whose sequence in the region reads GCCGTC.
  • Nae endonuclease was used to independently verify the differences between the two sequences. Nael was used instead of Hpal because Nael cleaves DNA less frequently than Hpal. As expected, the pEC clone exhibited one more cleavage site in its inserts than its pEJ counterpart. This also provided retrospective verification of the in vitro recombinant clones. The allele specifying transformation and abnormal p21 migration was seen to precisely co-segregate with the allele disal ⁇ lowing Nael cleavage at this site.
  • Figure 8 presents the results of an Nael restriction enzyme assay of the EJ oncogene and its corresponding proto-oncogene. According to the methods described it was determined that there should exist an Nael restriction site in the proto-oncogene which should be lost in the altera- tion which produced the oncogene.
  • Molecular clones of the oncogene (pEJ) and proto-oncogene (pEC) and the plasmid into which each was cloned (pBR322) were each purified by known methods. One microgram of each was cut with the enzyme Nael and the resultant fragments were resolved by electro ⁇ phoresis through a 15 percent bis-acrylamide gel.
  • Lane 1 is 0 x 174 DNA cut with the enzyme Haelll as a marker lane producing bands of known size
  • Lane 2 is pBR322 cut with Nael showing fragments originating
  • Lane 3 is Nael cleaved pEJ DNA; and. Lane 4 is Nael cleaved pEC DNA.
  • the pEJ DNA contains a band migrating with a molecular weight of 1200 base pairs which is missing in the pEC lane.
  • the pEC lane however, has two extra bands, one of 400 bases and the other of 800 bases in length which are missing in pEJ lane.
  • the Nael site in pEC which allows cleavage of the 1200 bp band into two bands of 400 and 800 bases, is lost in the creation of the EJ oncogene.
  • valine for glycine might not be expected to have such a profound change in the function of the p21 protein. Nevertheless, several considerations appear to confer importance on this structural alteration.
  • the 37 residue long amino acid sequences encoded by the first exons of the two cellular genes are identi ⁇ cal, indicating great evolutionary conservation of this region.
  • the Kirsten transforming gene is closely related to the v-Ha-ras gene. See Dhar, R., Ellis, R.W., Shih, T.Y. , Oroszlan, S., Shapiro, B., Maizel, J. , Lowy, D.R. and Scolnick, E.M. Science 217; 934-936 (1982) .
  • Harvey sarcoma virus encoded p21s While sequence information is not available on the cellular homologue of the v-Ki-ras, it can be speculated that a conversion from the glycine to a new amino acid residue at position 12 may also have been involved in the activation of this ras oncogene.
  • a second consideration stems from examination of the specific amino acid changes observed.
  • glycine is replaced by an amino acid having a relatively bulky side chain.
  • Glycine represents an anomaly among the 20 amino acids because it lacks a side chain. Consequently, it is able to participate in extremes of bending and folding of the polypeptide backbone and is the strongest breaker of alpha-helices. See Cantor, C.R. and Schimmel, P.R. Biophysical Chemistry, Vol. I, p. 303, W.H. Freeman and Co., San Fran ⁇ cisco (1980) .
  • valine or arginine represent abrupt changes in the local stereochemistry of a protein.
  • loss of glycine at residue 12 represents a significant change in an essential domain of the p21 protein.
  • a conse ⁇ quence of this change may be a ⁇ onformational shift of the protein, leading in turn to the aberrant electrophoretic migration or processing of p21 proteins.
  • a second, more important con- sequence is a profound effect on the function of the p21 protein. It is likely that this altera ⁇ tion affects interaction of the p21 with cellular targets.
  • Oncogenes of other tumors have also been traced to ras genes. Specifically, colon and lung carcinomas have been found to carry oncogenes derived from activation of cellular Ki-ras genes. See Der, C. , Krontiris, T.G. and Cooper, G.M.
  • any test of the cleavability of the DNA at this site by these endonucleases constitutes a diagnostic test for the mutational alteration of this region of the proto-oncogene.
  • This test can be performed by treating DNAs of interest with Nael, for example, resolving the resultant fragments by agarose gel electro ⁇ phoresis, transferring the resolved fragments to a cellulose nitrate filter, and detecting the transferred fragments by incubation of the filter with a radiolabelled, sequence-specific probe followed by radioautography.
  • the procedures are well known. See Southern, J. Mol. Biol. , 98, 503-17 (1975).
  • sequence probe used in such experiments can derive from any one of a number of DNA seg ⁇ ments which overlap the region of the proto-onco ⁇ gene, or which lie closely adjacent to this region of the proto-oncogene.
  • the sequence probe could be the Nael fragment of the oncogene beginning at the Nael site to the left of the altered codon and ending at the Nael site to the right of it.
  • DNA of a cell carrying the normal proto-oncogene would be cleaved into two parts at this site by the Nael, while DNA of the EJ bladder carcinoma oncogene is unaffected at this site by treatment with a Nael endonuclease.
  • This assay may be made general for the alteration of DNA of a proto-oncogene for its corresponding oncogene. Sensitivity to cleavage by a restriction endonuclease at a DNA sequence of either the proto-oncogene or oncogene, but not the other, is the fundamental concept.
  • Another consequence of the change in amino acid sequence of the p21 protein encoded by the proto-oncogene from the p21 protein coded by the oncogene relates to detection of either by speci ⁇ fic seralogical reagents.
  • the seralogical re ⁇ agents can be specific for the normal, proto- oncogene-specified amino acid sequence at this site of the protein, or be specific for the altered oncogene-specified amino acid sequence at this site of the protein.
  • Other seralogical reagents could be employed that are reacted with a region of the protein that is unaltered, and consequently reactive with either normal or abnormal forms of the p21 protein.
  • p21 protein encoded for by the normal site of the proto-oncogene, or by the altered site of the oncogene can be isolated.
  • protein segments could be used to produce antibodies by standard antibody production techniques.
  • pro ⁇ ducing p ⁇ lyclonal antibodies such proteins would be employed to immunize a host, such as a rabbit or a rat, and antibodies to the protein would be collected from serum obtained from the host.
  • monoclonal antibodies could be produced employing cells which produce antibodies to the protein produced by the isolated gene seg ent in typical fusion techniques for forming hybridoma cells.
  • these techniques involve the fusing of the antibody producing cell with a cell having immortality, such as a myeloma cell, to provide a fused cell hybrid which has immortality and is capable of producing the desired antibody; in this case, an antibody to the normal or altered segment of p21 protein coded for by the isolated gene segment.
  • the hybrid cells are then cultured under conditions conducive to the production of antibody after which antibody is collected from the cell culture medium.
  • Such techniques for producing monoclonal antibodies have been well described in the literature. See, for example, U.S. Patent Nos. 4,172,124 and
  • seralogical reagents can be developed by the known methods. See Walter, G. , Scheidtmann, K.H. , Carbone, A., Laudaro, A.P. and Doolittle, R.F. , Proc. Nat'l. Acad. Sci. USA, 77, 5197-5200 (1980); Lerner, R. A., Green, N. , Alexander, H. , Liu, F.T., Sut- cliffe, J.G., and Schinnick, T.M., Proc. Nat'l. Acad. Sci. USA, 7 , 3403-3407 (1981).
  • a peptide segment can be syn ⁇ thesized by a standard organic synthetic tech ⁇ nique, the sequence of this peptide corresponding precisely with the amino sequence of the region of interest of the protein to be studied.
  • This peptide can then be coupled to a carrier protein and injected into a suitable host (e.g., mouse) to illicit an immune response.
  • a suitable host e.g., mouse
  • the serum of the animal immunized in this fashion is then used to immune-precipitate both the immunizing peptide, and more importantly, the protein carrying this amino acid sequence in one of its domains.
  • a serum can be made against an oligopeptide sequence (e.g., decapeptide) spanning the amino acid residue site that is altered during the conversion of the normal proto-oncogene to the oncogene.
  • oligopeptide sequence e.g., decapeptide
  • Such serum can be made against the normal peptide sequence, or alternatively, against the altered sequence.
  • the specificity of the immunoglobulin-antigen interaction will insure that the serum reacting with one oligopeptide will only react with the protein bearing the same, corresponding sequence in one of its domains and not cross-react with a protein bearing an altered version of this sequence in one of its domains.
  • P21 protein can be immune-precipitated from a tumor sample or from a tissue homogenate or from fluid released by an autolysing tumor fragment by use of the general, non-specific p21 serum that cross-reacts with domains of the protein (e.g., C-terminal) that are unaffected by the mutation- induced alterations described here.
  • the serum with specificity against the N-terminal normal peptides surrounding residue 12 can be used to immune-precipitate protein from the same lysate. If this N-terminal specific serum, which is able to immune-precipitate normal p21 from the non-pathological tissue, is unable to immune-precipitate p21 from a test tissue of interest, then the p21 of this test tissue can be
  • the above immune-precipitation can be used as a measurement of the presence of altered p21 in a tissue sample.
  • a series of peptide specific sera can be developed to diagnose which type of specific alteration has occurred to alter the normal amino acid sequence of this region into an abnormal sequence. For example, a list can be made of the amino acid replacements that can occur by simple point mutation at the codon encoding residue 12. For each of these replacements, a new version of the oligopeptide sequence of this region can be deduced, and a corresponding peptide synthesized for use as described above. Each one of these sera would be specifically reactive with the altered p21 corres ⁇ ponding to the oligopeptide fragment used to induce the serum in question.
  • immunoglobulin can be radiolabelled either by direct iodination, or indirectly, by incubation of the immunoglobulin with a second, radiolabelled immunoglobulin that reacts with constant regions of the first immunoglobulin.
  • the techniques have particular application and advantage, of course, in detecting differences between oncogenes and proto-oncogenes.
  • Members of the ras family of genes have been discussed previously.
  • the techniques described herein also lend themselves to finding differences between proto-oncogenes and oncogenes other than members of the ras family. For example, differ ⁇ ences between the oncogene present in the HL-60 cell line, known to be responsible for promylo- ⁇ ytic leukemia, certain colon cancers, and Hairy cell leukemia, and its proto-oncogene could be determined using procedures described herein. These differences could then be employed in assays of the type described.
  • A. Develop an in. vitro assay for the activity of a gene, the functioning or mal-func- tioning of which is responsible for the phenotype of a genetic disease.
  • Such _in vitro assay will, in general, depend upon an observable alteration in behavior of a cultured cell that has acquired the gene via gene transfer.
  • C. Use the isolated allele from Section B to isolate other allelic forms of the gene using recombinant DNA techniques. Thus, the normal allele could be used as sequence probe to enable identification and isolation of a variant, non-wild-type' allele.
  • D. Demonstrate the observably different and distinct behaviors of the wild-type allele and a non-wild type variant in the in vitro assay system.
  • ⁇ . Perform in vitro genetic recombination between the clones of the wild-type and non-wild- type allele followed by testing of the recombin ⁇ ants in the ⁇ n vitro assay system, assaying for the phenotype induced by a wild-type or non-wild- type allele in this system (Part D) .
  • Part F Having identified a crucially altered sequence (Part F) , the existence of which deter ⁇ mines the altered phenotype of the non-wild-type gene, identify one or more site-specific endonucleases (restriction enzymes) the cleavage recognition site of which was altered during the processes which converted a wild-type allele into a non-wild-type allele.
  • Part H Use the cloned wild-type gene as sequence probe to screen to DMAs of test samples or test tissue to determine whether or not said test DNA carries a sequence alteration in that gene, and that portion of said gene which has been previously shown (Part E) to be critical in affecting function of said gene and its non-wild- type allelic variants, screening for the presence or absence of the restriction endonuclease site (Part G) the alteration of which has previously been shown to affect functioning of the gene.
  • OMPI I Deduce the amino acid sequences encoded by the normal wild-type allele of the gene and its non-wild-type variant forms. Determine whether the previously mapped nucleotide sequence differ- ence, which has previously been shown to affect functioning of the gene (Part F) , affects as well the amino acid sequence of the proteins encoded by wild-type and non-wild-type alleles.
  • Part K Utilize said protein screening (Part K) to diagnose for the presence of proteins whose structure is important in mediating the phenotype of a genetic disease.
  • the invention described herein is useful in defining the differences between proto-oncogenes and their corresponding oncogenes, the proteins coded for by such genes, the preparation of antibodies to such proteins or portions thereof, and the use of such antibodies in assaying for the presence of such proto-oncogenes or oncogenes as a measure of carcinogenesis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • External Artificial Organs (AREA)

Abstract

On décrit ici des expériences destinées à définir les différences entre l'oncogène (21) de l'ADN isolé des cellules cancéreuses de la vessie chez l'homme et son proto-oncogène correspondant. Par une série de recombinaisons in vitro la différence a été isolée au départ sur un segment de 350 kb d'ADN; la mise en séquence a permis de définir la différence comme un changement du codon Gly12, ce qui fait que la protéine p21 de l'oncogène contient de la valine à un emplacement où la protéine p21 du proto-oncogène contenait de la glycine. On décrit également des analyses permettant de détecter une carcinogenèse sur la base de telles différences. Dans un type d'analyse, une enzyme de restriction spécifique soit du segment modifié soit du segment non-modifié d'ADN des gènes est utilisée pour détecter la carcinogenèse. Dans un autre type d'analyse on décrit des réactifs tels que l'anticorps spécifique soit de la protéine p21 exprimé à partir du proto-oncogène soit de la protéine p21 exprimé à partir de l'oncogène ou d'un site commun.
PCT/US1983/001517 1982-10-01 1983-09-29 Caracterisation et analyses d'oncogenes WO1984001389A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE8383903635T DE3382098D1 (de) 1982-10-01 1983-09-29 Charakterisierung von onkogenen und darauf beruhende bestimmungen.
JP58503483A JPH0642840B2 (ja) 1982-10-01 1983-09-29 発癌遺伝子の解明およびそれに基づく検定法
AT83903635T ATE59412T1 (de) 1982-10-01 1983-09-29 Charakterisierung von onkogenen und darauf beruhende bestimmungen.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/432,337 US4535058A (en) 1982-10-01 1982-10-01 Characterization of oncogenes and assays based thereon

Publications (1)

Publication Number Publication Date
WO1984001389A1 true WO1984001389A1 (fr) 1984-04-12

Family

ID=23715723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1983/001517 WO1984001389A1 (fr) 1982-10-01 1983-09-29 Caracterisation et analyses d'oncogenes

Country Status (6)

Country Link
US (3) US4535058A (fr)
EP (4) EP0241961B1 (fr)
JP (2) JPH0642840B2 (fr)
AT (3) ATE114820T1 (fr)
DE (3) DE3382765T2 (fr)
WO (1) WO1984001389A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175360A2 (fr) * 1984-09-19 1986-03-26 Cetus Corporation Anticorps contre les peptides et leurs utilisation dans la détection des produits d'oncogènes
EP0177814A2 (fr) * 1984-09-19 1986-04-16 Cetus Corporation Anticorps contre les peptides et leurs utilisation dans la détection des produits d'oncogènes
EP0190033A2 (fr) * 1985-01-29 1986-08-06 Oncogene Science, Inc. Anticorps monoclonal contre un dodécapeptide relatif au P21 de l'oncogène RAS
WO1986006494A3 (fr) * 1985-05-02 1987-03-26 Daniel Louvard Moyens pour le diagnostic in vitro de cellules malignesorigi naires du tube digestif
FR2589882A2 (fr) * 1985-11-13 1987-05-15 Pasteur Institut Moyens pour le diagnostic in vitro de cellules malignes originaires du tube digestif
US4762706A (en) * 1984-10-17 1988-08-09 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
EP0330878A2 (fr) * 1988-02-16 1989-09-06 F. Hoffmann-La Roche Ag Anticorps contre la protéine anti-ras
WO1989012697A1 (fr) * 1988-06-22 1989-12-28 The Board Of Regents Of The University Of Washingt Procede de detection de genes anormaux
EP0608004A2 (fr) * 1986-08-11 1994-07-27 MASSACHUSETTS EYE & EAR INFIRMARY ADN humaine pour le diagnostic du rétinoblastome
US5635389A (en) * 1985-05-02 1997-06-03 Institut Pasteur Antibodies which recognize and bind human villin
US5760203A (en) * 1988-08-10 1998-06-02 Chiron Corporation Gap gene sequences
US5763573A (en) * 1988-08-10 1998-06-09 Chiron Corporation GTPase activating protein fragments
US5853988A (en) * 1986-08-11 1998-12-29 Massachusetts Eye And Ear Infirmary Diagnosis of retinoblastoma
US6100067A (en) * 1989-04-12 2000-08-08 Institut Pasteur Molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a protein produced by P. falciparum at the sporozoite stage and in the hepatocytes
US6713619B1 (en) 1980-08-29 2004-03-30 Massachusetts Institute Of Technology Oncogenes and methods for their detection
US7223842B1 (en) 1986-08-11 2007-05-29 Massachusetts Eye And Ear Infirmary Detection of proteins whose absence is associated with a neoplasm
US7384735B1 (en) 1986-08-11 2008-06-10 Massachusetts Eye And Ear Infirmary Retinoblastoma nucleic acids

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935341A (en) * 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
USRE35491E (en) * 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US5030565A (en) * 1983-08-17 1991-07-09 Scripps Clinic And Research Foundation Polypeptide-induced monoclonal receptors to protein ligands
US5591587A (en) * 1983-08-17 1997-01-07 The Scripps Research Institute Polypeptide-induced monoclonal receptors to protein ligands
US5733738A (en) * 1983-08-17 1998-03-31 Ligand Pharmaceuticals Polypeptide-induced monoclonal receptors to protein ligands
US4681840A (en) * 1984-01-18 1987-07-21 The United States Of America As Represented By The Secretary Of Commerce Deoxyribonucleic acid molecules useful as probes for detecting oncogenes incorporated into chromosomal DNA
US4725550A (en) * 1984-01-19 1988-02-16 Research Foundation Of State University Of New York Novel mutation of the c-K-ras oncogene activated in a human lung carcinoma
US4683194A (en) * 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US5087571A (en) * 1984-06-22 1992-02-11 President And Fellows Of Harvard College Method for providing a cell culture from a transgenic non-human mammal
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
US4866166A (en) * 1984-08-31 1989-09-12 Cold Spring Harbor Laboratory Bioassay for transforming genes and genes detected thereby
US4701409A (en) * 1984-11-15 1987-10-20 The Wistar Institute Detection of B-cell neoplasms
US4735895A (en) * 1984-12-28 1988-04-05 Oncotech, Inc. Cancer susceptibility test
US5443956A (en) * 1985-01-29 1995-08-22 Oncogene Science, Inc. Detection, quantitation and classification of RAS proteins in body fluids and tissues
US4898932A (en) * 1985-01-29 1990-02-06 E. I. Du Pont De Nemours And Company Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US5028527A (en) * 1988-02-22 1991-07-02 Applied Bio Technology Monoclonal antibodies against activated ras proteins with amino acid mutations at position 13 of the protein
US5081230A (en) * 1987-07-08 1992-01-14 E. I. Dupont Denemours And Company Monoclonal antibodies reactive with normal and oncogenic forms of the ras p21 protein
US5084380A (en) * 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US6200764B1 (en) 1985-01-29 2001-03-13 Bayer Corporation Detection, quantitation and classification of ras proteins in body fluids and tissues
US4871838A (en) * 1985-07-23 1989-10-03 The Board Of Rijks Universiteit Leiden Probes and methods for detecting activated ras oncogenes
US5591582A (en) * 1985-07-23 1997-01-07 The Board Of Rijks Universiteit Leiden Methods for detecting activated RAS oncogenes
US6083709A (en) * 1985-08-21 2000-07-04 Osi Pharmaceuticals, Inc. Immunoassay for detection of mutant P53 polypeptide in serum
US4946773A (en) * 1985-12-23 1990-08-07 President And Fellows Of Harvard College Detection of base pair mismatches using RNAase A
US5320941A (en) * 1986-06-06 1994-06-14 Dallan Young DNA sequence encoding mas onhcogene, polypeptides encoded therefrom and diagnostic and other methods based therefrom
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US4820631A (en) * 1986-07-30 1989-04-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Deletion mutants and monoclonal antibodies against ras proteins
EP0262942A1 (fr) * 1986-09-30 1988-04-06 Smithkline Beecham Corporation Transfection de cellule
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5789235A (en) * 1987-03-23 1998-08-04 Tackett; Scott E. Modifying cell metabolism via extra-cellular nucleases
US4870161A (en) * 1987-09-25 1989-09-26 The United States Of America As Represented By The Department Of Health And Human Services Reagents and probes for distinguishing and isolating different GTP-binding proteins
CA1339069C (fr) * 1987-11-09 1997-07-29 Henry Lee Niman Recepteurs monoclonaux induits par des polypeptides pour ligans proteiniques
US5112737A (en) * 1988-02-22 1992-05-12 Applied Biotechnology, Inc. Monoclonal antibodies against activated ras proteins with amino acid mutations at position 13 of the protein
DE3809635C3 (de) * 1988-03-22 1996-06-20 Niehoff Kg Maschf Verfahren und Vorrichtung zur Herstellung eines spulenlosen Gebindes sowie ein mit dem Verfahren hergestelltes Gebinde
EP0767381B1 (fr) 1988-04-22 2004-01-28 Bayer Corporation Détection, quantification et classification de protéines RAS dans des fluides et des tissus corporels
EP0483249B1 (fr) * 1989-07-18 2003-04-23 OSI Pharmaceuticals, Inc. Methode permettant de moduler l'expression de genes par transcription et de decourvrir des substances chimiques pouvant agir comme modulateurs de l'expression de genes
US6203976B1 (en) * 1989-07-18 2001-03-20 Osi Pharmaceuticals, Inc. Methods of preparing compositions comprising chemicals capable of transcriptional modulation
US5665543A (en) * 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
US5776502A (en) 1989-07-18 1998-07-07 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression
ES2264239T3 (es) * 1990-06-27 2006-12-16 Princeton University Complejo de proteinas p53/p90'.
US5851764A (en) * 1990-10-25 1998-12-22 The Trustees Of Columbia University In The City Of New York Human prostate tumor inducing gene-1 and uses thereof
US6159751A (en) * 1990-10-25 2000-12-12 The Trustees Of Columbia University In The City Of New York Development of DNA probes and immunological reagents of human tumor associated antigens
WO1992008131A1 (fr) * 1990-10-25 1992-05-14 The Trustees Of Columbia University In The City Of New York Developement de sondes d'adn et reactifs immunologiques d'antigenes associes a une tumeur d'origine humaine
WO1992013091A1 (fr) * 1991-01-18 1992-08-06 Oncogene Science, Inc. Procede de modulation par transcription de l'expression genique d'oncogenes et de genes supprimant les tumeurs
US6110700A (en) * 1991-03-11 2000-08-29 The General Hospital Corporation PRAD1 cyclin and its cDNA
US6150398A (en) * 1991-05-08 2000-11-21 The United States Of America As Represented By The Department Of Health And Human Services Methods for the treatment of cancer
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
WO1993022457A1 (fr) * 1992-04-24 1993-11-11 Massachusetts Institute Of Technology Criblage servant a detecter une variation genetique
US5726024A (en) * 1993-08-02 1998-03-10 Health Research, Inc. p53as protein and antibody therefor
US5747650A (en) * 1993-08-02 1998-05-05 Health Research, Inc. P53AS protein and antibody therefor
US6965009B1 (en) 1993-08-02 2005-11-15 Health Research, Inc. p53 as protein and antibody therefor
US5688918A (en) * 1993-08-02 1997-11-18 Health Research, Inc. p53as protein and antibody therefor
WO1995013398A1 (fr) * 1993-11-12 1995-05-18 Oncor, Inc. Detection du cancer de la vessie
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US6524578B1 (en) 1996-07-10 2003-02-25 Scott E. Tackett Use of nuclease to reduce wrinkles and discolorations in humans
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US6300077B1 (en) 1996-08-14 2001-10-09 Exact Sciences Corporation Methods for the detection of nucleic acids
US5952178A (en) 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6300081B1 (en) 1996-11-15 2001-10-09 Cornell Research Foundation, Inc. Activated ras interaction assay
US6268136B1 (en) 1997-06-16 2001-07-31 Exact Science Corporation Methods for stool sample preparation
US6406857B1 (en) 1997-06-16 2002-06-18 Exact Sciences Corporation Methods for stool sample preparation
US20020064792A1 (en) * 1997-11-13 2002-05-30 Lincoln Stephen E. Database for storage and analysis of full-length sequences
US6503718B2 (en) 1999-01-10 2003-01-07 Exact Sciences Corporation Methods for detecting mutations using primer extension for detecting disease
US6280947B1 (en) 1999-08-11 2001-08-28 Exact Sciences Corporation Methods for detecting nucleotide insertion or deletion using primer extension
ES2269102T3 (es) 1999-02-25 2007-04-01 Exact Sciences Corporation Procedimientos para conservar la integridad del adn.
US6964846B1 (en) * 1999-04-09 2005-11-15 Exact Sciences Corporation Methods for detecting nucleic acids indicative of cancer
US6849403B1 (en) 1999-09-08 2005-02-01 Exact Sciences Corporation Apparatus and method for drug screening
US6586177B1 (en) 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
AU4714201A (en) * 1999-12-07 2001-06-18 Exact Sciences Corporation Supracolonic aerodigestive neoplasm detection
US6919174B1 (en) * 1999-12-07 2005-07-19 Exact Sciences Corporation Methods for disease detection
WO2003071252A2 (fr) 2002-02-15 2003-08-28 Exact Sciences Corporation Procedes d'analyse d'evenements moleculaires
US20040259101A1 (en) * 2003-06-20 2004-12-23 Shuber Anthony P. Methods for disease screening
JP5095216B2 (ja) 2003-11-14 2012-12-12 ローラス セラピューティクス インコーポレーテッド アリールイミダゾールおよびその抗癌剤としての使用
US20080241827A1 (en) * 2004-05-10 2008-10-02 Exact Sciences Corporation Methods For Detecting A Mutant Nucleic Acid
WO2005113769A1 (fr) * 2004-05-14 2005-12-01 Exact Sciences Corporation Procédé servant à stabiliser des échantillons biologiques pour une analyse d'acides nucléiques
WO2006026654A2 (fr) * 2004-08-27 2006-03-09 Exact Sciences Corporation Procede pour detecter une recombinaison
US9109256B2 (en) 2004-10-27 2015-08-18 Esoterix Genetic Laboratories, Llc Method for monitoring disease progression or recurrence
DE102005011022A1 (de) * 2005-03-10 2006-09-14 Häfner & Krullmann Gmbh Verfahren zum Bewickeln einer Spule mit strangförmigem Wickelgut
US9777314B2 (en) * 2005-04-21 2017-10-03 Esoterix Genetic Laboratories, Llc Analysis of heterogeneous nucleic acid samples
ES2370054T3 (es) * 2005-08-24 2011-12-12 Bristol-Myers Squibb Company Biomarcadores y procedimientos para determinar la sensibilidad a moduladores del receptor del factor de crecimiento epidérmico.
KR20160058960A (ko) 2013-10-04 2016-05-25 압토스 바이오사이언시스 인코포레이티드 암을 치료하기 위한 조성물과 방법
JP2019517566A (ja) * 2016-06-10 2019-06-24 ライデン、ブロック 創傷パッキングを用いて創傷を治療するためのシステム及び方法
EP3703685A4 (fr) 2017-10-30 2021-07-28 Aptose Biosciences Inc. Arylimidazoles pour le traitement du cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395486A (en) * 1981-08-19 1983-07-26 Medical College Of Ga. Research Inst., Inc. Method for the direct analysis of sickle cell anemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299815A (en) * 1980-02-08 1981-11-10 Hoffmann-La Roche Inc. Carcinoembryonic antigen determination
US4368262A (en) * 1981-03-23 1983-01-11 Research Corporation Diagnostic test for the detection of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395486A (en) * 1981-08-19 1983-07-26 Medical College Of Ga. Research Inst., Inc. Method for the direct analysis of sickle cell anemia

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 97, No. 5, 2 August 1982 (Columbus, Ohio, US) M.E. FURTH et al.: "Monoclonal Antibodies to the p21 Products of the Transforming Gene of Harvey Murine Sarcoma Virus and of the Cellular Ras Gene Family", see page 425, Abstract No. 37279b, J. Virol. 1982, 43(1), 294-304 (Eng.) *
CHEMICAL ABSTRACTS, Vol. 98, No. 19, 9 May 1983 (Columbus, Ohio, US) C. SHIH et al.: "Isolation and Analysis of Molecular Clones of Human Oncogenes", see page 100, Abstract No. 155814r, Annu. Symp. Fundam. Cancer Res., (Proc.) 1982 (Pub. 1983) 35th (Perspect. Genes Mol. Biol. Cancer), 307-11 (Eng.) *
Nature, Vol. 289, 12 February 1981, B.Z. SHILO et al.: "Unique Transforming Gene in Carcinogen-Transformed Mouse Cells", pages 607-609, see the entire document cited in the application *
Nature, Vol. 297, 10 June 1982 E. CHANG et al.: "Tamorigenic Transformation of Mammalian cells Induced by a Normal Human gene Homologous to the Oncogene of Harvey Murine Sarcoma Virus", pages 479-483, see the entire document *
Nature, Vol. 297, 10 June 1982 L. PARADA et al.: "Human EJ Bladder Carcinoma Oncogene is Homologue of Harvey Sarcoma virus Ras Gene" pages 474-479, see the entire document cited in the application *
Nature, Vol. 298, 22 July 1982 E. SANTOS et al.: "T24 Human Bladder Carcinoma Oncogene is an Activated Form of the Normal Human Homologue of BALB- & Harvey-MSV Transforming Genes", pages 343-347, see the entire document cited in the application *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713619B1 (en) 1980-08-29 2004-03-30 Massachusetts Institute Of Technology Oncogenes and methods for their detection
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
EP0177814A2 (fr) * 1984-09-19 1986-04-16 Cetus Corporation Anticorps contre les peptides et leurs utilisation dans la détection des produits d'oncogènes
EP0175360A2 (fr) * 1984-09-19 1986-03-26 Cetus Corporation Anticorps contre les peptides et leurs utilisation dans la détection des produits d'oncogènes
EP0177814A3 (fr) * 1984-09-19 1987-12-02 Cetus Corporation Anticorps contre les peptides et leurs utilisation dans la détection des produits d'oncogènes
EP0175360A3 (fr) * 1984-09-19 1988-03-30 Cetus Corporation Anticorps contre les peptides et leurs utilisation dans la détection des produits d'oncogènes
US4762706A (en) * 1984-10-17 1988-08-09 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
EP0190033A2 (fr) * 1985-01-29 1986-08-06 Oncogene Science, Inc. Anticorps monoclonal contre un dodécapeptide relatif au P21 de l'oncogène RAS
EP0190033A3 (en) * 1985-01-29 1987-11-11 E.I. Du Pont De Nemours And Company Monoclonal antibody against a ras oncogene p21 related dodecapeptide
US5635389A (en) * 1985-05-02 1997-06-03 Institut Pasteur Antibodies which recognize and bind human villin
WO1986006494A3 (fr) * 1985-05-02 1987-03-26 Daniel Louvard Moyens pour le diagnostic in vitro de cellules malignesorigi naires du tube digestif
FR2589882A2 (fr) * 1985-11-13 1987-05-15 Pasteur Institut Moyens pour le diagnostic in vitro de cellules malignes originaires du tube digestif
EP0608004A2 (fr) * 1986-08-11 1994-07-27 MASSACHUSETTS EYE & EAR INFIRMARY ADN humaine pour le diagnostic du rétinoblastome
EP0608004A3 (en) * 1986-08-11 1994-08-10 Massachusetts Eye & Ear Infirm Human dna in the diagnosis of retinoblastoma.
US7384735B1 (en) 1986-08-11 2008-06-10 Massachusetts Eye And Ear Infirmary Retinoblastoma nucleic acids
US5853988A (en) * 1986-08-11 1998-12-29 Massachusetts Eye And Ear Infirmary Diagnosis of retinoblastoma
US7223842B1 (en) 1986-08-11 2007-05-29 Massachusetts Eye And Ear Infirmary Detection of proteins whose absence is associated with a neoplasm
EP0330878A3 (fr) * 1988-02-16 1990-05-02 F. Hoffmann-La Roche Ag Anticorps contre la protéine anti-ras
EP0330878A2 (fr) * 1988-02-16 1989-09-06 F. Hoffmann-La Roche Ag Anticorps contre la protéine anti-ras
WO1989012697A1 (fr) * 1988-06-22 1989-12-28 The Board Of Regents Of The University Of Washingt Procede de detection de genes anormaux
US5760203A (en) * 1988-08-10 1998-06-02 Chiron Corporation Gap gene sequences
US5763573A (en) * 1988-08-10 1998-06-09 Chiron Corporation GTPase activating protein fragments
US6100067A (en) * 1989-04-12 2000-08-08 Institut Pasteur Molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a protein produced by P. falciparum at the sporozoite stage and in the hepatocytes

Also Published As

Publication number Publication date
JPH05281228A (ja) 1993-10-29
JP2573770B2 (ja) 1997-01-22
EP0239162A2 (fr) 1987-09-30
DE3382098D1 (de) 1991-02-07
EP0120958B1 (fr) 1990-12-27
US4786718A (en) 1988-11-22
DE3382765T2 (de) 1995-05-04
EP0239162A3 (en) 1989-08-16
ATE114820T1 (de) 1994-12-15
DE3382767D1 (de) 1995-01-26
EP0239162B1 (fr) 1994-12-14
US5300631A (en) 1994-04-05
DE3382767T2 (de) 1995-10-19
EP0241961A2 (fr) 1987-10-21
ATE59412T1 (de) 1991-01-15
DE3382765D1 (de) 1995-01-12
JPS60500002A (ja) 1985-01-10
ATE115588T1 (de) 1994-12-15
EP0241961B1 (fr) 1994-11-30
EP0241961A3 (en) 1989-01-25
US4535058A (en) 1985-08-13
JPH0642840B2 (ja) 1994-06-08
EP0605789A1 (fr) 1994-07-13
EP0120958A1 (fr) 1984-10-10

Similar Documents

Publication Publication Date Title
US4535058A (en) Characterization of oncogenes and assays based thereon
Tabin et al. Mechanism of activation of a human oncogene
EP0453560B1 (fr) Localisation et caracterisation du gene tumoral de wilms
EP0412116B1 (fr) Detection d'expression de genes neu et produits
US4935341A (en) Detection of point mutations in neu genes
CA1340827C (fr) Methodes diognostiques detetection de lymphome chez l'etre humain
CA1252046A (fr) Methodes de depistage du cancer
US6943011B2 (en) Localization and characterization of the Wilms' tumor gene
EP0518650B1 (fr) Fixation de P53 sur l'ADN au moyen d'une séquence spécifique
US4701409A (en) Detection of B-cell neoplasms
US7267955B2 (en) Method for detecting loss of wild-type p53
US6677312B1 (en) Methods for restoring wild-type p53 gene function
JP3256227B2 (ja) Ｄｎａプローブの開発およびヒト腫瘍関連抗原の免疫学的試薬
US6329198B1 (en) Production and use of human nm23 protein and antibodies therefor
US6713619B1 (en) Oncogenes and methods for their detection

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): JP

AL Designated countries for regional patents

Designated state(s): AT BE CH DE FR GB LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1983903635

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1983903635

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1983903635

Country of ref document: EP